Monday, February 25, 2013

I want proof of this claim by AMRI

Also in this week's C&EN, an interesting writeup of Informex (the fine chemicals trade show) by Rick Mullin:
The fine and custom chemical executives gathered in Anaheim, Calif., last week for the annual Informex exhibition reported that business continues to be strong in pharmaceuticals. A shift in contract manufacturing from China and India back to the West has provided a steady boost to the sector, they said. 
Susan B. Billings, business development manager for Albany Molecular Research Inc., said drug and biotech companies are increasingly interested in working with contract research and manufacturing firms with integrated drug discovery capabilities, “and they are willing to pay for it.” 
At the end of collaboration, Billings said, they want to have meaningful outcomes such as a clinical candidate that they can advance. AMRI has increased its medicinal chemistry resources in the U.S. by 50% since 2011, she said.
I would really be interested to know what this means. Have they expanded their medicinal chemists by 50% in the US? I doubt it. How did they measure to get this number? Does this include the Lilly contractor folks? Also in the same article:
Meanwhile, Asymchem, a U.S.-based firm that does all its manufacturing in China, has been investing in specialized flow chemistry and enzymatic manufacturing, according to Matt Johnson, director of chemical development. “We don’t want to be continually perceived as the cheap alternative to Western supply,” Johnson said.
Good luck there.

3 comments:

  1. I'd bet it's the Lilly folks...

    ReplyDelete
  2. "AMRI has increased its medicinal chemistry resources in the U.S. by 50% since 2011, she said."

    I, also, would be interested to know what this means. AMRI's opex in Q3 2011 was $58 million (same as Q1 2011, COGS was $42 mill), compared with $47 (COGS $44 mill) million in Q312.

    ReplyDelete
  3. I'm willing to bet that claim is valid only because of the wonders of financial engineering through m&a and partnerships, including the hayluron acquisition and the pact with ge healthcare. Probably nothing of substance for med chemists in the claim.

    ReplyDelete